Author/Authors :
ÖNALAN, Tuğba Karşıyaka Devlet Hastanesi - Göğüs Hastalıkları Kliniği, Turkey , BAYSAK, Ayşegül 2İzmir Üniversitesi - Tıp Fakültesi - Göğüs Hastalıkları Anabilim Dalı, Turkey , EMRE, Jülide Çeldir Turgutlu Devlet Hastanesi - Göğüs Hastalıkları Kliniği, Turkey , ÖZDEMİR, Özer Özel Egepol Hastanesi - Göğüs Hastalıkları Kliniği, Turkey , ÖZHAN, Mustafa Hikmet Ege Üniversitesi - Tıp Fakültesi - Göğüs Hastalıkları Anabilim Dalı, Turkey
Abstract :
Aim: Data from recent studies revealed that the use of combinations of inhaled corticosteroids and long acting beta 2 agonists (LABA) may increase pneumonia risk in chronic obstructive pulmonary disease (COPD) patients. The aim of this retrospective study is to compare the occurence of pneumonia in COPD patients who received regularly inhaled corticosteroid and LABA combinations with the patients who received inhaled LABA only. Materials and Methods: Sixty-two COPD patients were included in the study. Patients were divided into 2 groups according to the inhaled agents they used; “combination group” (31 patients; 26 male, 5 female; median age±SD: 68±9) and “LABA group” (31 patients; 27 male, 4 female; median age±SD: 66±8). Medical recotds of patients were retrospectively evaluated and all patients were contacted via telephone.Results: Ten patients in combination group had severe or very severe COPD (FEV1 50%) versus 8 patients in LABA group. Seventeen episodes (54%) of pneumonia was detected in the combination group, whereas 10 (32%) in LABA group (p=0.06). Diabetes mellitus was present as a comorbidity in two patients in the combination group and in three in the LABA group. Conclusion: Since study population was limited, statistical difference between the two groups was found to be insignificant. But, there was a trend of higher incidence of pneumonia in the combination group, similar to previous studies
NaturalLanguageKeyword :
COPD , combination inhaled agents , LABA , pneumonia
